Resistance mutation info of drug
| Drug General Information | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug ID | D0D4YZ | |||||||||||||||
| Drug Name | PSI-7977 | |||||||||||||||
| Synonyms | 1190307-88-0; SOVALDI; PSI 7977; GS-7977; GS 7977; UNII-WJ6CA3ZU8B; WJ6CA3ZU8B; CHEBI:85083; Sofosbuvir (PSI-7977, GS-7977); Hepcvir; Hepcinat; HSDB 8226; 2-((5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy)phenoxyphosphorylamino)propionic acid isopropyl ester; Sofosbuvir [USAN:INN]; Resof; SoviHep; Sovaldi (TN); Sofosbuvir (JAN/USAN); Sofosbuvir(PSI-7977); GTPL7368; SCHEMBL2010114; CHEMBL1259059; AMMD00019; EX-A389; MolPort-028-720-482; isopropyl (2S)-2-[[[(2R, | |||||||||||||||
| Drug Type | Small molecular drug | |||||||||||||||
| Company | Gilead Sciences | |||||||||||||||
| Structure |
|
|||||||||||||||
| Drug Resistance Mutations | ||||||||||||||||
| Target Name | HCV RNA-directed RNA polymerase (NS5B) | Target Info | ||||||||||||||
| Gene Name | NS5B | |||||||||||||||
| Uniprot ID | POLG_HCVJA(2420-3010) | |||||||||||||||
| Species | Hepatitis C virus genotype 1b | |||||||||||||||
| Reference Sequence |
SMSYTWTGALITPCAAEESKLPINPLSNSLLRHHSMVYSTTSRSASLRQKKVTFDRLQVL DDHYRDVLKEMKAKASTVKARLLSIEEACKLTPPHSAKSKFGYGAKDVRSLSSRAVNHIR SVWEDLLEDTETPIDTTIMAKNEVFCVQPEKGGRKPARLIVFPDLGVRVCEKMALYDVVS TLPQAVMGPSYGFQYSPGQRVEFLVNTWKSKKCPMGFSYDTRCFDSTVTENDIRTEESIY QCCDLAPEARQAIRSLTERLYVGGPLTNSKGQNCGYRRCRASGVLTTSCGNTLTCYLKAT AACRAAKLQDCTMLVNGDDLVVICESAGTQEDAAALRAFTEAMTRYSAPPGDPPQPEYDL ELITSCSSNVSVAHDASGKRVYYLTRDPTTPLARAAWETVRHTPVNSWLGNIIMYAPTLW ARMILMTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLPQIIERLHGLSAFSLHSYSPG EINRVASCLRKLGVPPLRVWRHRARSVRAKLLSQGGRAATCGKYLFNWAVKTKLKLTPIP AASQLDLSGWFVAGYNGGDIYHSLSRARPRWFMLCLLLLSVGVGIYLLPNR [Hepatit is C virus genotype 1b] |
|||||||||||||||
| Targeted Disease | HCV infection | |||||||||||||||
| Drug Resistance Mutations |
|
|||||||||||||||
| References | ||||||||||||||||
| REF 1 | Lam, A.M. et al. Selection and characterization of heaptitis C virus replicons using combinations of NS3 protease and NS5B non-nucleoside inhibitors or combination of NS5B nucleotide inhibitors. . in International HIV & Hepatitis Virus Drug Resistance Workshop, Vol. 15 Supplement 2 A28 (Dubrovnik, Croatia, 2010). | |||||||||||||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.